NCT05084365

A 6-month Study to Evaluate Sulforaphane Effects in PD Patients

Status unknown Phase 2 Last updated 6 July 2023

What this trial tests

Phase 2 trial testing Sulforaphane in Parkinson Disease in 100 participants. Status unknown.

Timeline

28 November 2021

Primary endpoint
15 November 2023

31 December 2023

Quick facts

Lead sponsor	Central South University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	100
Start date	28 November 2021
Primary completion	15 November 2023
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

• Sulforaphane — full drug profile →
• Placebo

Conditions studied

• Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Central South University

Who can join

Adults 40 to 75, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parkinson's disease (PD) is a second common neurodegenerative disease. More than 6 million individuals worldwide have Parkinson disease. No disease-modifying pharmacologic treatments are available. Current medical treatment is symptomatic, focused on improvement in motor (eg, tremor, rigidity, bradykinesia) and nonmotor (eg, constipation, cognition, mood, sleep) signs and symptoms. Accumulating evidence suggests the important role for inflammation and oxidative stress in the pathogenesis of PD. Sulforaphane extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. Previous studies suggested sulforaphane is useful in dopaminergic neuron survival. In this study, the investigator attempts to evaluate the efficacy and safety of sulforaphane in PD patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting NLRP3 Inflammasome With Nrf2 Inducers in Central Nervous System Disorders.
   Tastan B, Arioz BI, Genc S. · · 2022 · cited 56× · PMID 35418995 · DOI 10.3389/fimmu.2022.865772
2. Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment.
   Yang X, Liu Y, Cao J, Wu C, et al · · 2025 · cited 42× · PMID 40258841 · DOI 10.1038/s41420-025-02491-z
3. Thioredoxin (Trx): A redox target and modulator of cellular senescence and aging-related diseases.
   Yang B, Lin Y, Huang Y, Shen YQ, et al · · 2024 · cited 39× · PMID 38232457 · DOI 10.1016/j.redox.2024.103032
4. Plant-Derived Bioactive Compounds in the Management of Neurodegenerative Disorders: Challenges, Future Directions and Molecular Mechanisms Involved in Neuroprotection.
   Shoaib S, Ansari MA, Fatease AA, Safhi AY, et al · · 2023 · cited 37× · PMID 36986610 · DOI 10.3390/pharmaceutics15030749
5. Alpha synuclein post translational modifications: potential targets for Parkinson's disease therapy?
   Brembati V, Faustini G, Longhena F, Bellucci A. · · 2023 · cited 27× · PMID 37305556 · DOI 10.3389/fnmol.2023.1197853
6. Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases.
   Plascencia-Villa G, Perry G. · · 2023 · cited 23× · PMID 37569861 · DOI 10.3390/ijms241512486
7. Parkinson's disease therapy: what lies ahead?
   Wolff A, Schumacher NU, Pürner D, Machetanz G, et al · · 2023 · cited 19× · PMID 37147404 · DOI 10.1007/s00702-023-02641-6
8. Targeting Microglia in Neuroinflammation: H3 Receptor Antagonists as a Novel Therapeutic Approach for Alzheimer's Disease, Parkinson's Disease, and Autism Spectrum Disorder.
   Thomas SD, Abdalla S, Eissa N, Akour A, et al · · 2024 · cited 18× · PMID 39065682 · DOI 10.3390/ph17070831